Journal of Bone Oncology

Aims & Scope

The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer.

As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces.

Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject.

The areas covered by the journal include: Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment) Preclinical models of metastasis Bone microenvironment in cancer (stem cell, bone cell and cancer interactions) Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics) Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management) Bone imaging (clinical and animal, skeletal interventional radiology) Bone biomarkers (clinical and translational applications) Radiotherapy and radio-isotopes Skeletal complications Bone pain (mechanisms and management) Orthopaedic cancer surgery Primary bone tumours Clinical guidelines Multidisciplinary care Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,680.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

  Citation: 209

  Authors: Peyman, Matti S., Jean-Jacques, Michael, Maria Luisa, Jean Yves, M. Carola, Claus-C., Tobie, Rod, G. David, Cyrus, Bente, Santiago, John, Nasser, Xavier, Erik Fink, Andreas, Rene, Robert E.

• Benign tumours of the bone: A review

  Citation: 191

  Authors: David N., Theo, Myutan, Jochem A.

• Metastatic bone disease: Pathogenesis and therapeutic options

  Citation: 166

  Authors: Stella, Robert, Janet, Francesco

• Advances in immune checkpoint inhibitors for bone sarcoma therapy

  Citation: 138

  Authors: Pichaya, Dylan C., Scott D., Francis J., Zhenfeng

• Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

  Citation: 133

  Authors: Aude I., Marta, Marie-Françoise, Dominique

• Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review

  Citation: 121

  Authors: Ruben, Erwin, Marc, Piet, Charlotte, Erik

• The role of tumour-associated macrophages in bone metastasis

  Citation: 119

  Authors: Sofia, Jorma

• Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study

  Citation: 99

  Authors: Xiaoyi, Jian, Jinyi, Hua, Bingbing, Lulu, Chen, Yanfang, Jing, Jianming

• The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond

  Citation: 96

  Authors: Tomalika Rahmat

• The role of osteoblasts in bone metastasis

  Citation: 93

  Authors: Penelope D